References

1. Glassia, Alpha-1 Proteinase Inhibitor (Human) prescribing information; Baxter Healthcare Corporation, Westlake Village, CA.


13. Campos MA, Kueppers F, Stocks JM et al. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: A multicenter randomized, double-blind, crossover study (SPARK) Clinical Trial Identifier: NCT01213043; *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2013;10,6;687-695.


